Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

A chemotherapy-free combination of HRS-4642 and adebrelimab achieved a 43.2% objective response rate in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

• Why it matters: KRAS G12D mutations are present in about 40% of pancreatic ductal adenocarcinoma cases and create an immunosuppressive tumor environment, limiting effective treatments and highlighting the need for targeted therapies.
• What they did: The phase 1/2 trial involved 48 patients, with dose escalation confirming safety and establishing the recommended phase 2 dose; efficacy was assessed through response rates, survival metrics, and adverse events.
• The result: The regimen demonstrated manageable toxicity and promising antitumor activity, with median overall survival of 11.5 months, supporting further research into this targeted, chemotherapy-free approach.